Business & Finance The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
By
· November 16, 2026 · 1 min read
This article was originally published by
MarketWatch
and is republished here under license.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Related
Chipmaker stocks tumbled after the US moved to further restrict China’s access to advanced artificial intelligence chips and servers in…
By
· November 17, 2026 · 1 min read
The airline said there was no impact on flights in progress and there was no indication the outage was a…
By
· November 17, 2026 · 1 min read
CNBC's Jim Cramer pushed back against fears that Nvidia's leadership shake-up could unravel the AI boom.…
By
· November 16, 2026 · 1 min read
Leave a Reply